reference/19469882

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19469882

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, N.I.H., Extramural
endingPage	4265
issn	0732-183X 1527-7755
issueIdentifier	32
pageRange	4260-4265
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	4260
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ab80a732b5df33e85751c0a758afb577 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_bcb538be81300dc8e034ad1c63fc7600 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_a920cb561afa794d7290c8e92740998e
bibliographicCitation	Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintás-Cardama A, Garcia-Manero G, Rios MB, Cortes JE. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011 Nov 10;29(32):4260–5. PMID: 21990394; PMCID: PMC3221527.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc68003ec9d8e11b647ada3756e7b965 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f2e73ca33ee15ba233980af7634aabb0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cbef71c6c9ee38c2d2fb7df759bcb6c6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b6d00d3aba027043e0cfebb59b17c883 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_98246eabf16e75d088310ed84ef52e0c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_386cf7e222997ebd16e954edf7d1c580 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e605c269adda7e5090582abbca5a213a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bc34ddc88a28e12990e522742a21f0cb
date	2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC3221527 https://doi.org/10.1200/jco.2011.36.0693 https://pubmed.ncbi.nlm.nih.gov/21990394
isPartOf	https://portal.issn.org/resource/ISSN/0732-183X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023 https://portal.issn.org/resource/ISSN/1527-7755
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
discusses	http://id.nlm.nih.gov/mesh/M0017888 http://id.nlm.nih.gov/mesh/M0457532
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D011505Q000037 http://id.nlm.nih.gov/mesh/D015466Q000188 http://id.nlm.nih.gov/mesh/D047428Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D015466Q000401 http://id.nlm.nih.gov/mesh/D015466Q000235 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_aa29d6984108c685bd651011d6733c00 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3062316 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9727 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9729 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644241 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129879136 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247851103 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128433595

Total number of triples: 57.